Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
P/E ratio for Fate Therapeutics, Inc. (FATE)
P/E ratio as of 2023: -2.29
According to Fate Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.29. At the end of 2022 the company had a P/E ratio of -3.83.
P/E ratio history for Fate Therapeutics, Inc. from 2011 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -2.29 |
| 2022 | -3.83 |
| 2021 | -26.87 |
| 2020 | -43.99 |
| 2019 | -13.66 |
| 2018 | -10.83 |
| 2017 | -5.97 |
| 2016 | -2.38 |
| 2015 | -2.86 |
| 2014 | -3.97 |
| 2013 | -1.77 |
| 2012 | -4.12 |
| 2011 | -4.37 |